We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

76 hedge funds and large institutions have $153M invested in KalVista Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 19

1% more funds holding

Funds holding: 75 → 76 (+1)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

11.74% less ownership

Funds ownership: 85.72% → 73.98% (-12%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

53% less capital invested

Capital invested by funds: $328M → $153M (-$175M)

Holders
76
Holders Change
+1
Holders Change %
+1.33%
% of All Funds
1.67%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
15
Increased
21
Reduced
19
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$2.91M
2
Northern Trust
Northern Trust
Illinois
+$1.69M
3
PAMU
Pictet Asset Management (UK)
United Kingdom
+$1.47M
4
Squarepoint
Squarepoint
New York
+$851K
5
O
OrbiMed
New York
+$626K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$30.1M
2
DM
Deerfield Management
New York
-$5.28M
3
Invesco
Invesco
Georgia
-$4M
4
ACP
Acuta Capital Partners
California
-$3.04M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$513K +$139K +8,575 +24%
SSA
27
Schonfeld Strategic Advisors
New York
$471K -$1.06M -65,800 -62%
O
28
OrbiMed
New York
$449K +$626K +38,733 New
Morgan Stanley
29
Morgan Stanley
New York
$444K +$604K +37,378 +3,972%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$428K -$35.3K -2,187 -6%
SCM
31
Stonepine Capital Management
Oregon
$383K +$534K +33,033 New
N
32
Nuveen
North Carolina
$374K -$480K -29,706 -48%
BC
33
Birchview Capital
Vermont
$348K +$485K +30,000 New
BFM
34
Boothbay Fund Management
New York
$346K +$482K +29,825 New
AG
35
Algert Global
California
$333K +$65.7K +4,069 +16%
Charles Schwab
36
Charles Schwab
California
$317K – – –
Wellington Management Group
37
Wellington Management Group
Massachusetts
$303K +$421K +26,069 New
ACP
38
Acuta Capital Partners
California
$290K -$3.04M -188,000 -88%
DCM
39
DAFNA Capital Management
California
$287K – – –
Renaissance Technologies
40
Renaissance Technologies
New York
$221K +$307K +19,028 New
Barclays
41
Barclays
United Kingdom
$209K -$80.3K -4,973 -22%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$208K – – –
Swiss National Bank
43
Swiss National Bank
Switzerland
$204K – – –
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$203K +$283K +17,500 New
TI
45
Trexquant Investment
Connecticut
$183K +$255K +15,799 New
Millennium Management
46
Millennium Management
New York
$164K +$69.9K +4,324 +44%
ECM
47
ExodusPoint Capital Management
New York
$158K +$220K +13,600 New
VEA
48
Virtus ETF Advisers
New York
$147K -$11.4K -707 -5%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$139K – – –
JG
50
Jefferies Group
New York
$131K +$182K +11,250 New
1
2
3 4

KALV Hedge Fund Activity: Q3 2019 in Review

76 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2019, worth a combined $153M — down 53% from $328M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KALV positions and 14 closed out — a net gain of 1 holder — while 21 added to existing stakes and 19 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $2.91M. The largest seller was Vivo Capital, exiting entirely with an estimated $30.1M sold.

  • 76 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2019, up from 75 in Q2 2019.
  • Funds reported $153M of KalVista Pharmaceuticals stock for Q3 2019, down 53% quarter-over-quarter.
  • 15 funds opened new KalVista Pharmaceuticals positions in Q3 2019 and 14 closed out, a net change of +1 holder.
  • The largest KalVista Pharmaceuticals buyer in Q3 2019 was Eventide Asset Management, an estimated $2.91M added.
  • The largest KalVista Pharmaceuticals seller in Q3 2019 was Vivo Capital, an estimated $30.1M sold.

Based on aggregated 13F filings for Q3 2019.